The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment.

Abstract

Recurrent pericarditis (RP) is a troublesome and debilitating complication of acute pericarditis. Although the etiopathogenesis of this condition remains unknown, an intricate overlap of autoimmune and autoinflammatory pathways has been hypothesized to explain its beginning and recurrence over time. The majority of cases are defined as "idiopathic", reflecting our awkwardness to unravel the intimate mechanisms of RP. Given the possible occurrence of anti-nuclear, anti-heart and anti-intercalated disk antibodies as well as the association with peculiar human leukocyte antigen haplotypes, an autoimmune contribution has been claimed to specify the nature of RP. However, the most innovative pathogenic scenario of RP has been conferred to the innate immune system, mainly involving neutrophils and macrophages that produce a large amount of interleukin (IL)-1 via inflammasome activation. The clinical resemblance of RP with autoinflammatory diseases that may be marked by symptomatic serositis, high fevers and strikingly increased inflammatory parameters further suggests a similar inflammasome-mediated pathogenesis. Aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of therapy in RP, whereas colchicine is recommended on top of standard anti-inflammatory therapy, due to its role in inhibiting the IL-1 converting enzyme (caspase 1) within the inflammasome as well as the release of additional pro-inflammatory mediators and reactive oxygen species. With regard to treatment of RP refractory to NSAIDs and colchicine, blockade of IL-1 is the most relevant advance achieved in the last decade: the outstanding effect of the short-acting IL-1 receptor antagonist anakinra has been first recognized in the pediatric population, giving a proof of its practical feasibility. Over a more recent time, a growing experience with anakinra deriving from both large and small studies has further confirmed that RP might be regarded as an IL-1-mediated disease. This review aims to provide a contemporary insight into the mechanisms leading to RP as well as into the most recent literature data showing the beneficial approach originating from IL-1 blockade in this intriguing disorder.

• Authors: Giuseppe Lopalco, Donato Rigante, Luca Cantarini, Massimo Imazio, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Marco Fornaro, Bruno Frediani, Mariangela Nivuori, Antonio Brucato, Florenzo Iannone
• Journal: Trends in cardiovascular medicine (Trends Cardiovasc Med) Vol. 31 Issue 5 Pg. 265-274 (07 2021) ISSN: 1873-2615 [Electronic] United States
• PMID: 32376492 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020. Published by Elsevier Inc.

Chemical References

• Anti-Inflammatory Agents
• Inflammasomes
• Inflammation Mediators
• Interleukin 1 Receptor Antagonist Protein
• Interleukin-1

Topics

• Animals
• Anti-Inflammatory Agents (adverse effects, therapeutic use)
• Autoimmunity (drug effects)
• Humans
• Immunity, Innate (drug effects)
• Inflammasomes (antagonists & inhibitors, metabolism)
• Inflammation Mediators (antagonists & inhibitors, metabolism)
• Interleukin 1 Receptor Antagonist Protein (adverse effects, therapeutic use)
• Interleukin-1 (antagonists & inhibitors, metabolism)
• Monocytes (drug effects, immunology, metabolism)
• Myocardium (immunology, metabolism)
• Neutrophils (drug effects, immunology, metabolism)
• Pericarditis (diagnosis, drug therapy, immunology, metabolism)
• Recurrence
• Signal Transduction
• Treatment Outcome